• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酸性鞘磷脂酶缺乏症和戈谢病:瘦人肝肿大、脾肿大及高密度脂蛋白胆固醇降低的诊断不足且常可治疗的病因。

Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals.

作者信息

Mistry Pramod K, Cassiman David, Jones Simon A, Lachmann Robin, Lukina Elena, Prada Carlos E, Wasserstein Melissa P, Thurberg Beth L, Foster Meredith C, Patel Reema M, Underhill Lisa H, Peterschmitt M Judith

机构信息

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Department of Gastroenterology-Hepatology, University Hospitals Leuven, Leuven, Belgium.

出版信息

Hepatol Commun. 2025 Jan 7;9(1). doi: 10.1097/HC9.0000000000000621. eCollection 2025 Jan 1.

DOI:10.1097/HC9.0000000000000621
PMID:39774103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11717527/
Abstract

BACKGROUND

Acid sphingomyelinase deficiency (ASMD) and Gaucher disease type 1 (GD1) are rare inherited sphingolipid disorders with multisystemic manifestations, including liver disease and dyslipidemia. Despite effective treatments, insufficient disease awareness frequently results in diagnostic delays during which irreversible complications occur. We delineated the shared and distinctive features of hepatic, splenic, and lipoprotein phenotypes in ASMD and GD1.

METHODS

We analyzed baseline hepatic, splenic, and lipoprotein phenotypes of untreated adults in pivotal trials of ASMD (ASCEND, N=36) and GD1 (ENGAGE, N=40).

RESULTS

The mean cohort ages were 34.8 years in ASMD and 31.8 years in GD1. Most patients had normal or low body mass index. Moderate hepatosplenomegaly (mean volume in multiples of normal) was common in both cohorts (hepatomegaly 1.53±0.42 and 1.40±0.32, respectively; splenomegaly 11.45±4.36 and 13.20±5.91, respectively). Liver function tests were mildly elevated in ASMD but normal in GD1. In both disorders, mean HDL cholesterol (mg/dL) was profoundly low (22.23±9.14 ASMD; 26.25±8.08 GD1) and correlated inversely with liver volume (r=-0.45 ASMD, p=0.005; r=-0.50 GD1, p=0.001) and spleen volume (r=-0.60 ASMD, p=0.0001; r=-0.63 GD1, p<0.0001). Mean LDL cholesterol (mg/dL) was elevated in ASMD (145.86±49.80) but low in GD1 (68.85±22.53). HDL cholesterol correlated inversely with serum concentrations of lyso-sphingomyelin in ASMD (r=-0.48, p=0.003) and glucosylsphingosine in GD1 (r=-0.63, p<0.0001).

CONCLUSIONS

ASMD and GD1 should be considered in differential diagnosis of patients with unexplained liver and lipid abnormalities, especially young, lean adults with very low HDL and hepatosplenomegaly. HDL emerged as a potential biomarker of disease activity in these sphingolipid disorders.

摘要

背景

酸性鞘磷脂酶缺乏症(ASMD)和1型戈谢病(GD1)是罕见的遗传性鞘脂紊乱疾病,具有多系统表现,包括肝脏疾病和血脂异常。尽管有有效的治疗方法,但疾病认知不足常常导致诊断延迟,在此期间会发生不可逆的并发症。我们描述了ASMD和GD1在肝脏、脾脏和脂蛋白表型方面的共同特征和独特特征。

方法

我们分析了ASMD(ASCEND,N = 36)和GD1(ENGAGE,N = 40)关键试验中未治疗成年人的基线肝脏、脾脏和脂蛋白表型。

结果

ASMD队列的平均年龄为34.8岁,GD1队列的平均年龄为31.8岁。大多数患者的体重指数正常或偏低。两个队列中均常见中度肝脾肿大(平均体积为正常倍数)(肝肿大分别为1.53±0.42和1.40±0.32;脾肿大分别为11.45±4.36和13.20±5.91)。ASMD患者的肝功能检查轻度升高,但GD1患者正常。在这两种疾病中,平均高密度脂蛋白胆固醇(mg/dL)极低(ASMD为22.23±9.14;GD1为26.25±8.08),且与肝脏体积呈负相关(ASMD中r = -0.45,p = 0.005;GD1中r = -0.50,p = 0.001)以及脾脏体积呈负相关(ASMD中r = -0.60,p = 0.0001;GD1中r = -0.63,p < 0.0001)。ASMD患者的平均低密度脂蛋白胆固醇(mg/dL)升高(145.86±49.80),而GD1患者则偏低(68.85±22.53)。在ASMD中,高密度脂蛋白胆固醇与溶血鞘磷脂的血清浓度呈负相关(r = -0.48,p = 0.003),在GD1中与葡萄糖神经鞘脂呈负相关(r = -0.63,p < 0.0001)。

结论

对于原因不明的肝脏和脂质异常患者,尤其是年轻、体型偏瘦且高密度脂蛋白极低以及肝脾肿大的成年人,鉴别诊断时应考虑ASMD和GD1。在这些鞘脂紊乱疾病中,高密度脂蛋白成为疾病活动的潜在生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/cc7bc64bdb05/hc9-9-e0621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/188097069734/hc9-9-e0621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/ffa3df994851/hc9-9-e0621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/f2db652d4818/hc9-9-e0621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/14b1026f5089/hc9-9-e0621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/3476f7f7298f/hc9-9-e0621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/60d99757a996/hc9-9-e0621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/75d1445ce774/hc9-9-e0621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/cc7bc64bdb05/hc9-9-e0621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/188097069734/hc9-9-e0621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/ffa3df994851/hc9-9-e0621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/f2db652d4818/hc9-9-e0621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/14b1026f5089/hc9-9-e0621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/3476f7f7298f/hc9-9-e0621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/60d99757a996/hc9-9-e0621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/75d1445ce774/hc9-9-e0621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adbb/11717527/cc7bc64bdb05/hc9-9-e0621-g008.jpg

相似文献

1
Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals.酸性鞘磷脂酶缺乏症和戈谢病:瘦人肝肿大、脾肿大及高密度脂蛋白胆固醇降低的诊断不足且常可治疗的病因。
Hepatol Commun. 2025 Jan 7;9(1). doi: 10.1097/HC9.0000000000000621. eCollection 2025 Jan 1.
2
Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis.戈谢病与酸性鞘磷脂酶缺乏症之间的异同:一种辅助诊断的算法
Eur J Intern Med. 2023 Feb;108:81-84. doi: 10.1016/j.ejim.2022.11.028. Epub 2022 Nov 26.
3
Acid sphingomyelinase deficiency and Gaucher disease in adults: Similarities and differences in two macrophage storage disorders.成人酸性鞘磷脂酶缺乏症和戈谢病:两种巨噬细胞贮积症的异同
JIMD Rep. 2024 Jul 4;65(5):330-340. doi: 10.1002/jmd2.12420. eCollection 2024 Sep.
4
Neonatal cholestasis is an early liver manifestation of children with acid sphingomyelinase deficiency.新生儿胆汁淤积症是酸性鞘磷脂酶缺乏症患儿的早期肝脏表现。
BMC Gastroenterol. 2022 May 9;22(1):227. doi: 10.1186/s12876-022-02310-0.
5
Chronic acid sphingomyelinase deficiency diagnosed in infancy/childhood in Polish patients: 2024 update.婴儿期/儿童期诊断的慢性酸性鞘磷脂酶缺乏症:波兰患者的 2024 年更新。
Adv Clin Exp Med. 2024 Oct;33(10):1163-1168. doi: 10.17219/acem/193696.
6
Glycoprotein non-metastatic protein B (GPNMB) plasma values in patients with chronic visceral acid sphingomyelinase deficiency.慢性内脏酸性鞘磷脂酶缺乏症患者的糖蛋白非转移性蛋白 B(GPNMB)血浆值。
Mol Genet Metab. 2023 Aug;139(4):107631. doi: 10.1016/j.ymgme.2023.107631. Epub 2023 Jul 9.
7
Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity.评估高密度脂蛋白作为戈谢病活性的循环生物标志物。
J Inherit Metab Dis. 2011 Apr;34(2):429-37. doi: 10.1007/s10545-010-9271-7. Epub 2011 Feb 3.
8
Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria.成人慢性内脏酸性鞘磷脂酶缺乏症的自然病程:迈向治疗标准的第一步。
J Inherit Metab Dis. 2025 Jan;48(1):e12789. doi: 10.1002/jimd.12789. Epub 2024 Aug 23.
9
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.依利格鲁司他治疗戈谢病 1 型 8 年的结果:来自 2 期试验的最终结果。
Am J Hematol. 2019 Jan;94(1):29-38. doi: 10.1002/ajh.25300. Epub 2018 Oct 26.
10
Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.前瞻性研究儿童和成人慢性酸性鞘磷脂酶缺乏症的自然病史:十一年观察。
Orphanet J Rare Dis. 2021 May 10;16(1):212. doi: 10.1186/s13023-021-01842-0.

引用本文的文献

1
Advanced strategies for detecting acid sphingomyelinase deficiency type B with attenuated phenotypes.检测具有轻度表型的B型酸性鞘磷脂酶缺乏症的先进策略。
Orphanet J Rare Dis. 2025 May 26;20(1):252. doi: 10.1186/s13023-025-03746-9.

本文引用的文献

1
The impact of sphingomyelin on the pathophysiology and treatment response to olipudase alfa in acid sphingomyelinase deficiency.鞘磷脂对酸性鞘磷脂酶缺乏症的病理生理学及对olipudase alfa治疗反应的影响。
Genet Med Open. 2024 Aug 23;2:101888. doi: 10.1016/j.gimo.2024.101888. eCollection 2024.
2
A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.团结的呼声:迈向更精确且以患者为中心的非酒精性脂肪性肝病命名法之路。
Hepatology. 2023 Jul 1;78(1):3-5. doi: 10.1097/HEP.0000000000000412. Epub 2023 May 22.
3
Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease.
重要的是,要在疑似患有戈谢病的患者中纳入酸性鞘磷脂酶缺乏症(ASMD)的鉴别诊断。
Mol Genet Metab. 2023 May;139(1):107563. doi: 10.1016/j.ymgme.2023.107563. Epub 2023 Mar 30.
4
Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).酸性鞘磷脂酶缺乏症(尼曼-匹克病 A、B 和 A/B 型)的共识临床管理指南。
Orphanet J Rare Dis. 2023 Apr 17;18(1):85. doi: 10.1186/s13023-023-02686-6.
5
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.2123 例戈谢氏病 1 型患者的癌症风险和丙种球蛋白异常在国际戈谢氏病组织戈谢氏病注册研究中的表现。
Am J Hematol. 2022 Oct;97(10):1337-1347. doi: 10.1002/ajh.26675. Epub 2022 Aug 24.
6
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.一项评估奥利普酶阿尔法酶替代疗法治疗成人慢性酸性鞘磷脂酶缺乏症(ASMD)的随机、安慰剂对照临床试验:一年的结果。
Genet Med. 2022 Jul;24(7):1425-1436. doi: 10.1016/j.gim.2022.03.021. Epub 2022 Apr 26.
7
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.基因组分析在非酒精性脂肪性肝病瘦型个体临床评估中的新作用。
Hepatology. 2021 Oct;74(4):2241-2250. doi: 10.1002/hep.32047.
8
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.依洛尤单抗治疗戈谢病 1 型 4.5 年后的临床结局:III 期 ENGAGE 试验的最终结果。
Am J Hematol. 2021 Sep 1;96(9):1156-1165. doi: 10.1002/ajh.26276. Epub 2021 Jul 11.
9
Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.前瞻性研究儿童和成人慢性酸性鞘磷脂酶缺乏症的自然病史:十一年观察。
Orphanet J Rare Dis. 2021 May 10;16(1):212. doi: 10.1186/s13023-021-01842-0.
10
Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.尼曼-匹克病患者接受阿加糖酶β治疗后 PCSK9 和载脂蛋白 B100 的变化。
Orphanet J Rare Dis. 2021 Feb 27;16(1):107. doi: 10.1186/s13023-021-01739-y.